Frank Tsai, MD
Hematology & Oncology · Scottsdale, AZNPI 1518134691
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 53.5% of the total. Reporting peaked in 2023 at $2,254 and has fallen 87.2% since, to $289 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 46 payments — averaging $78.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$2K
- Steris Corporation$344
- Intuitive Surgical$276
- E.r. Squibb & Sons, L.L.C.$269
- Icotec Medical Inc.$162
- Johnson & Johnson$149
- plus $475 from 15 others
Across 219 payments — averaging $4271.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$517K
- Merck$211K
- Incyte Corporation$127K
- AstraZeneca$42K
- AbbVie$27K
- F. Hoffmann-la Roche AG$12K
What the payments were for
- Speaking & faculty fees$1,92353%
- Food & beverage$1,63946%
- Education$351%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $1,923 |
| Steris Corporation | 2 | $344 |
| Intuitive Surgical | 3 | $276 |
| E.r. Squibb & Sons, L.L.C. | 6 | $269 |
| Icotec Medical Inc. | 1 | $162 |
| Johnson & Johnson | 2 | $149 |
| Pfizer | 7 | $77 |
| Merck | 6 | $70 |
| Lilly USA, LLC | 3 | $56 |
| Gilead(2 entities) | 2 | $44 |
| Amgen | 2 | $37 |
| Exelixis Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $27 |
| CTI Biopharma Corp. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Boston Scientific | 1 | $18 |
| EMD Serono, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Bayer | 1 | $14 |
| Tactile Systems Technology Inc | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,598 in reported general payments places this provider in the 40th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 49 | $534,928 |
| XtandiEnzalutamide | 33 | $454,782 |
| PomalystPomalidomide | 17 | $429,503 |
| TagrissoOsimertinib Mesylate | 24 | $354,478 |
| RevlimidLenalidomide | 21 | $345,872 |
| TabrectaCapmatinib Hydrochloride | 13 | $276,989 |
| KisqaliRibociclib Succinate | 13 | $197,875 |
| CalquenceAcalabrutinib Maleate | 11 | $177,118 |
| SprycelDasatinib | 11 | $135,041 |
| EliquisApixaban | 144 | $119,351 |
| Abiraterone Acetate | 35 | $79,407 |
| XareltoRivaroxaban | 18 | $13,814 |
| Enoxaparin Sodium | 20 | $5,741 |
| Dexamethasone | 70 | $1,390 |
| Ondansetron OdtOndansetron | 90 | $966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $269 | $564,54428 claims |
| AstraZenecaTagrisso, Calquence | $15 | $531,59635 claims |
| PfizerEliquis | $77 | $119,351144 claims |
| Johnson & JohnsonXarelto | $149 | $13,81418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 261 hematology & oncology providers in Arizona.
Other hematology & oncology in Scottsdale
- Jeffrey SchriberScottsdale$715K
- Tanios Bekaii-SaabScottsdale$527K
- Rajesh KukunoorScottsdale$499K
- Yousef ZakhariaScottsdale$214K
- Thai HoScottsdale$190K
- Alan BryceScottsdale$157K
- Daniel AhnScottsdale$91K
- Brendan CurleyScottsdale$87K
- Alexander StewartScottsdale$76K
- Saurabh ChhabraScottsdale$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.